Samsonite Corporation (OTCBB: SAMC), Organetix Inc. (OTCBB: OGTX), BrainStorm Cell Therapeutics (OTCBB: BCLI), ALONG Mobile Technologies Inc. (OTCBB: AGMB), Protein Polymer Technologies, Inc. (OTCBB: PPTI), Ceragenix Pharmaceuticals, Inc. (OTCBB: ...

  Chat real-time with other investors about SAMC, by clicking this link: http://www.stockwire.com/SAMC
 
  Samsonite Corporation, one of the world's largest designers, manufacturers,   distributors and marketers of luggage, casual bags, business cases and   travel-related products announced today that it has entered into a definitive   merger agreement to be acquired by funds managed and advised by CVC Capital   Partners ("CVC"), a leading global private equity firm. The all-cash transaction   is valued at approximately $1.7 billion, including the assumption of debt.
 
  Under the terms of the agreement, CVC will acquire all of the   outstanding common stock of Samsonite for $1.49 per share in cash.
 
  The   transaction was unanimously approved by the Board of Directors of Samsonite.
 
  Entities controlled by Ares Management LLC, Bain Capital Partners, LLC   and Teachers' Private Capital, the private investment arm of Ontario Teachers'   Pension Plan, ("Principal Shareholders") who collectively own approximately 85%   of Samsonite's common stock, have agreed to approve the transaction and have   entered into a written consent and voting agreement with CVC in this regard. The   written consent and voting agreement provides, among other things, that the   Principal Shareholders will deliver written consents approving the merger.
 
  The transaction is expected to close during the fourth quarter of 2007   and is subject to customary closing conditions, including regulatory review in   the US and Europe. CVC has received certain funds debt financing commitments   from third-party financing sources and, accordingly, closing is not subject to   the receipt of financing.
 
  Marcello Bottoli, CEO of Samsonite, said: "We   believe that this transaction delivers excellent value to all our shareholders.   I am excited to continue our successful journey to create the world's leading   travel lifestyle brand together with CVC Capital Partners." A representative for   the Principal Shareholders commented: "Ares Management LLC, Bain Capital and   Ontario Teachers' Pension Plan would like to thank Marcello Bottoli, the rest of   the management team and the employees of Samsonite for their significant efforts   during our ownership period in transforming the company into the world's leading   premium, global travel brand. We wish Samsonite and its new owners continued   success." Hardy McLain and Luigi Lanari of CVC stated, "CVC Capital Partners is   delighted to have reached agreement to acquire Samsonite, the world's leading   travel lifestyle brand. We look forward to working with Marcello Bottoli and his   team to realise the full potential of the brand. China and India present   particularly interesting opportunities for growth." Merrill Lynch International   acted as financial advisor and Skadden, Arps, Slate, Meagher & Flom (UK) LLP   acted as legal advisor to Samsonite in connection with the transaction. Kirkland   & Ellis LLP acted as legal advisor to the Principal Shareholders in   connection with the transaction. UBS and Lehman Brothers Inc. acted as financial   advisors and Paul, Weiss, Rifkind, Wharton & Garrison LLP and SJ Berwin LLP   acted as legal advisors to CVC.
 
  Chat real-time with other investors about OGTX, by clicking this link: http://www.stockwire.com/OGTX
 
  Organetix Inc. (OTCBB: OGTX)
 
  Organetix Inc. has announced today the execution of a Letter of Intent   ("LOI") to acquire New York based media firm Kid Fitness, Inc. ("Kid Fitness").   Under terms of the Letter of Intent (valid for 180 days), shareholders of   Organetix would end up with 36% of the combined company, subsequent to the   proposed merger. All future financing activities will be mutually dilutive. Both   management teams are committed to working towards a definitive merger agreement   ("definitive") as quickly as possible.
 
  Kid Fitness has developed   interactive media based programs to effectively combat the growing national   health concern known as Child Obesity. The Company has a multi year contract   with American Public television, a national program distributor for PBS (Public   Broadcast System). Kid Fitness has just completed series 200 which consists of   13 episodes produced in high definition, and is now available in more than 82   million American households. Each episode consists of fictional animal   characters (i.e. Brenda the Butterfly, Markey the Monkey) that simulate various   exercises with animal movements and provide children with a fun and informative   interactive experience.
 
  The Kid Fitness (PBS) series was directed by   Emmy-award winning director Steve Feldman, who was honored for "Outstanding   Director in a Children's Series" in 2002. Mr. Feldman previously directed   episodes of Barney, Sesame Street, and Lazytown. The Kid Fitness writing team   consists of Emmy-award winner, Mallory Louis, award winning writer Lynn   Kestin-Sessler, and the highly experienced Mark Valenti. To learn more about the   Kid Fitness television series and fictional characters, please visit the   Company's interactive website at www.kidfitnesstv.com.
 
  In addition Kid   Fitness has to date partnered with the National Association of Sports &   Physical Education ("NASPE"). NASPE is the country's preeminent authority for   physical education and a recognized leader in sports and physical activity. With   the help of NASPE, Kid Fitness has developed a 7 minute activity break to be   used in public school classrooms across the United States. This exercise program   satisfies the Federally mandated 7 minute daily fitness break, throughout U.S.   public schools. In early 2007 Kid Fitness rolled out its 7 minute fitness   program into all New York City public school classrooms (Kindergarten through   2nd Grade).
 
  In 2004, the federal government mandated "wellness policies"   to increase physical activity for children throughout the school day. During   2007, school districts are required to have wellness policies in place. By the   end of 2008, Kid Fitness, Inc. anticipates that its 7 minute fitness break could   be used by as many as 500,000 classrooms nationwide. This provides the company   with potentially significant branding and revenue opportunities.
 
  Earlier   this year, Kid Fitness and the New York Mets launched a multi- faceted   partnership including the first Kid Fitness day at Shea stadium prior to a   Sunday afternoon baseball game. More than 12,000 children participated in Kid   Fitness day and it was a resounding success. This partnership provides Kid   Fitness with an excellent opportunity to showcase and build its brand   recognition within the world of professional sports.
 
  Kid Fitness expects   to consummate additional partnerships over the course of the next few months. In   addition the Company is in negotiations with sponsors for both its PBS   television series as well as the classroom fitness kits. The long term goal of   the Company is to create a strong and trusted brand, synonymous with the health   and well being of children. Once fully funded, the Company plans to introduce   new product lines leveraging the strength and value of the Kid Fitness brand.
 
  Organetix CEO Seth M. Shaw stated, "We are very pleased to have signed   this LOI with a truly exciting and well positioned business as Kid Fitness. The   Company has established key alliances with exceptionally credible and important   partners. The greatest potential long term value is the ability of the Company   to further build the strength of the Kid Fitness brand through additional   alliances and securing the right corporate sponsors. Management will work hard   towards completing the definitive merger agreement later this month, although   there can be no guarantees a final agreement will be reached."
 
  Chat real-time with other investors about BCLI, by clicking this link: http://www.stockwire.com/BCLI
 
  BrainStorm Cell Therapeutics (OTCBB: BCLI)
  BrainStorm Cell Therapeutics, a leading developer of adult stem cell   products, announced on 7/3/07 that it has entered into an agreement to raise up   to $5 million from ACCBT Corporation, a company under the control of Mr. Chaim   Lebovits.
 
  The investments by ACCBT Corporation will be made in   installments, providing the Company with the working capital resources that it   needs as it operates its business, advances and further develops its   technologies and research. Assuming ACCBT Corporation completes all of the   contemplated investments in the Company, ACCBT Corporation will acquire and own   a majority of the outstanding common stock and warrants to purchase common stock   of the Company. The closing of the first investment installment is subject to   the Company first satisfying certain conditions, including customary closing   conditions, which are expected to be completed by August 30, 2007. Subsequent   installments are subject to discretion of ACCBT corporation .
 
  The   Company also announced that it has appointed Mr. Chaim Lebovits as its President   to lead the Company. Mr. Lebovits is an internationally known and respected   businessman and leader, and the owner of ACC holdings, a holding company acting   in the field of gas and oil development fields, gold mining and infrastructure.   ACC has three subsidiaries, (i) C&L, which focuses on oil production in West   Africa and operates an oil and gas field with proven reserves of 20 million   barrels of oil and an option to discover up to an additional 100 million barrels   of oil; (ii) ACC, which holds 10 permits for gold exploration in Burkina Faso;   and (iii) ACCBT, which focuses on new and emerging biotechnologies. Mr. Lebovits   has been at the forefront of mining and natural resource management in the   African region for close to a decade. He has spent years leading the exploration   and development of resources on behalf of world-leading firms. In this capacity   he has negotiated numerous, highly-successful deals on behalf of both African   governments and global mining concerns.
 
  "We are very proud to have Mr.   Chaim Lebovits join our management team, as he is a well-respected and   experienced business leader and entrepreneur," said Yoram Drucker, BrainStorm's   Chief Operating Officer. "The new funding will help us accelerate our safety   trials for Parkinson's disease as well as advance our other adult stem cell   therapy programs aimed at ALS, Multiple Sclerosis and other neurodegenerative   disorders." Chaim Lebovits commented, "The internationally-acclaimed scientific   team at BrainStorm has achieved remarkable results in developing a cutting-edge   stem cell technology and is well on its way to meeting the unmet need for   therapies targeting devastating medical disorders with multi-billion market   potential. I am looking forward to being a part of this dynamic organization."   Earlier this year BrainStorm announced the initiation of a safety trial using   the NurOwn technology in a primate animal model of Parkinson's disease. That   study is being carried out in collaboration with the Center for Applied Medical   Research (CIMA) of the University of Navarra in Pamplona, Spain.
 
  In   addition to moving ahead with the Company's Parkinson's disease program,   BrainStorm is also progressing with pre-clinical trials applying the Company's   stem cell technology to the treatment of ALS and Multiple Sclerosis.
 
  For   more information about BrainStorm Cell Therapeutics visit:   http://www.brainstorm-cell.com
 
  Chat real-time with other investors about AGMB, by clicking this link: http://www.stockwire.com/AGMB
 
  ALONG Mobile Technologies Inc. (OTCBB: AGMB)
 
  ALONG Mobile Technologies Inc., a leading   provider of wireless interactive entertainment products and services in China,   announced on 7/3/07 that it has been added to the NAI China Small-Cap Index. The   NAI China Small Cap Index (NAI-CSCI) is a leading market indicator featuring the   performance of publicly traded small-cap companies whose major business is   conducted in Greater China.
 
  Mr. Li Jianwei, Chairman and CEO of ALONG   Mobile Technologies Inc, stated, "We're pleased to be part of the NAI China   Small Cap Index. This further enhances our visibility in the American capital   markets and provides us with useful exposure to investors. Ludlow has built a   reputation for selecting quality Chinese companies which investors can trust and   we are honored to be chosen as one of them." Seeing tremendous growth in the   Chinese market, the NAI China Small Cap Index, created by NAI Interactive Ltd.,   introduces the rising investment opportunities to individual and institutional   investors. The number of Chinese companies listed in North America increases   exponentially in order to meet the high demand in investing in Chinese equities.   NAI-CSCI is aimed to bring in a new investment tool for the investment community   to follow the exciting stories of the Chinese small cap industry.
 
  For   more information about ALONG Mobile Technologies, Inc. visit:   http://www.alonggame.com
 
  Chat real-time with other investors about PPTI, by clicking this link: http://www.stockwire.com/PPTI
 
  Protein Polymer Technologies, Inc. (OTCBB: PPTI)
 
  Protein Polymer Technologies, Inc., a   biotechnology device company that is a pioneer in protein design and synthesis,   announced on 7/2/07 that they have entered into an agreement with a   multinational pharmaceutical and medical device company. According to the   agreement, PPTI will provide genetically engineered protein polymer biomaterials   for use as surgical sealants. "Our sealant products have consistently performed   well in evaluations by our corporate partners. We are excited about their   demonstrated potential and look forward to further product development," said   William N. Plamondon, CEO of Protein Polymer Technologies, Inc. Wound closure   after surgery or trauma using conventional sutures and staples sometimes results   in post-operative complications such as persistent internal bleeding, fluid   leaks after gastrointestinal surgery, or air leaks after lung surgery. In 2005,   it was estimated that 70 million surgical procedures worldwide would benefit   from the use of surgical sealants, glues and other wound closure products used   in conjunction with sutures and staples. PPTI believes its protein polymer   sealants and adhesives can improve the outcome of surgical wound closure by   substantially reducing fluid and air leaks, especially as applied to endoscopic   procedures in which access to the traumatized tissue is limited.
 
  PPTI is   also in discussions with several U.S. and international biotechnology and   medical device companies, which are evaluating PPTI's adhesion barrier and drug   delivery product applications. These products are intended to improve surgical   outcomes by reducing adhesion formation and delivering to the surgical site   beneficial pharmacological agents.
 
  For more information about Protein   Polymer Technologies, Inc. visit: http://www.ppti.com
 
  Chat real-time with other investors about CGXP, by clicking this link: http://www.stockwire.com/CGXP
 
  Ceragenix Pharmaceuticals, Inc. (OTCBB: CGXP)
 
  Ceragenix Pharmaceuticals, Inc., a   biopharmaceutical company focused on infectious disease and dermatology,   announced on 7/2/07 that researchers at the University of Pennsylvania led by   Dr. Paul Janmey and Dr. Robert Bucki, in collaboration with Dr. Paul B. Savage   of Brigham Young University, have demonstrated in a series of in vitro   experiments that an investigational drug compound known as CSA-13 shows promise   as a potential therapy to treat multidrug resistant Pseudomonas aeuroginosa   infections which are a leading cause of morbidity and mortality in patients with   cystic fibrosis. The research appears ahead of print in an advanced online   publication of the Journal of Antimicrobial Chemotherapy, the official journal   of the British Society for Antimicrobial Chemotherapy.
 
  In the reported   research, Dr. Bucki and his colleagues evaluated the activity of a CSA-13, a   member of the family of Ceragenin(TM) compounds being developed by Ceragenix.   CSA-13 is a synthetic non-peptide mimic of the naturally occurring antimicrobial   peptide found in the lung. The researchers found that CSA-13: -- Is   significantly more effective than positively charged antibacterial peptides   (LL-37) against a multidrug resistant strain of Pseudomonas aeuroginosa; -- Is   far less susceptible to inactivation by negatively charged components found in   the sputa of cystic fibrosis patients (DNA and F-actin); and that -- Is potent   even in cystic fibrosis sputum thereby suggesting potential for therapeutic use.
 
  "This new compound has the potential to be a significant advance in the   treatment of patients with cystic fibrosis and other lung infections," says   senior author Robert Bucki, a Senior Investigator at the University of   Pennsylvania's Institute for Medicine and Engineering.
 
  Normal healthy   lungs are protected against bacterial infection by the presence of naturally   occurring antimicrobial peptides such as LL-37 found in the lung fluid which   form part of the body's innate immune system. These positively charged   antimicrobial peptides are electrostatic attracted to the negatively charged   membranes of bacteria. Once attached to the invaders' membranes, the   antimicrobial peptides permeabilize and destroy the bacterial membranes leading   to bacterial cell death. This highly effective mechanism of protecting the lung   from bacterial infection does not work well in patients with cystic fibrosis as   those patients have much higher levels of other negatively charged components in   their sputum which bind to and inactivate the antimicrobial peptides. As a   result, patients with cystic fibrosis are at high risk for lung infections   throughout their lifetimes and the repeated bouts of lung infections scar the   lung tissue and ultimately rob the patients of their ability to breathe.
 
  "The conventional therapy used to treat Pseudomonas infections in cystic   fibrosis patients is Tobramycin but there are an increasing number of Tobramycin   resistant strains of Pseudomonas. There is an urgent need for the development of   new antibiotics to treat these and other gram-negative bacterial infections,"   said Steven Porter, Chairman and CEO of Ceragenix Pharmaceuticals. "Our goal is   to find a partner to help us advance development of this application."
 
  For more information about Ceragenix Pharmaceuticals, Inc. visit:   http://www.ceragenix.com

To see the complete Movers & Shakers Blog go to:  http://www.stockwire.com .

About Stockwire:
Stockwire is a company that is pioneering a new way to  research companies before you invest them. It's called a Stockumentary. A  Stockumentary is a documentary on a publicly traded company. Imagine a Dateline  NBC segment, but on a publicly traded company. We are the first company to ever  bring this type of quality research to investors in this format.